Published in Neurol Res on July 01, 2004
Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol (2009) 2.85
Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis (2010) 1.54
Heart failure and Alzheimer's disease. J Intern Med (2014) 1.54
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension (2009) 1.46
Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci (2013) 1.27
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology (2015) 1.21
Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med (2007) 1.13
The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci (2009) 1.13
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement (2009) 1.13
Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One (2011) 1.12
Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement (2011) 1.08
Iatrogenic risk factors for Alzheimer's disease: surgery and anesthesia. J Alzheimers Dis (2010) 1.00
Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener (2008) 0.96
Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease. Alzheimers Dement (2011) 0.93
Cerebral blood flow in Alzheimer's disease. Vasc Health Risk Manag (2012) 0.91
Stress, exercise, and Alzheimer's disease: a neurovascular pathway. Med Hypotheses (2011) 0.91
Expression of Tight Junction and Drug Efflux Transporter Proteins in an in vitro Model of Human Blood-Brain Barrier. Front Psychiatry (2012) 0.90
Heart disease as a risk factor for dementia. Clin Epidemiol (2013) 0.89
Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer's disease. Vasc Health Risk Manag (2008) 0.88
Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta (2011) 0.86
Autoregulation of cerebral blood flow to changes in arterial pressure in mild Alzheimer's disease. J Cereb Blood Flow Metab (2010) 0.84
Correlation of CT perfusion and CT volumetry in patients with Alzheimer's disease. Pol J Radiol (2010) 0.84
Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. Curr Gerontol Geriatr Res (2010) 0.83
Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's Disease. BMC Geriatr (2011) 0.83
Neurochemical profile of dementia pugilistica. J Neurotrauma (2013) 0.82
Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations. Neurochem Int (2012) 0.81
Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1. Neurobiol Aging (2008) 0.81
Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations. Am J Neurodegener Dis (2013) 0.81
Interhemispheric distribution of Alzheimer disease and vascular pathology in brain aging. Stroke (2008) 0.80
Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's disease. PLoS One (2014) 0.78
Getting the iron out: phlebotomy for Alzheimer's disease? Med Hypotheses (2009) 0.77
The occurrence of cerebrovascular atherosclerosis in Alzheimer's disease patients. Clin Interv Aging (2013) 0.76
Can Inconsistent Association between Hypertension and Cognition in Elders be Explained by Levels of Organochlorine Pesticides? PLoS One (2015) 0.75
A U-shaped Association Between Blood Pressure and Cognitive Impairment in Chinese Elderly. J Am Med Dir Assoc (2017) 0.75
Intracranial atherosclerosis and dementia: The Atherosclerosis Risk in Communities (ARIC) Study. Neurology (2017) 0.75
3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A (2005) 8.60
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (2004) 4.81
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med (2003) 3.78
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A (2004) 2.88
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol (2003) 2.36
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29
Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord (2014) 2.17
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med (2003) 1.79
Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett (2008) 1.76
Alzheimer's disease a century later. J Clin Psychiatry (2006) 1.74
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol (2010) 1.69
Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (2006) 1.64
Brain biochemistry in autopsied patients with essential tremor. Mov Disord (2011) 1.56
Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res (2006) 1.56
Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis (2010) 1.54
Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord (2009) 1.54
Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol (2007) 1.53
Dissembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson's disease patients. Mol Neurodegener (2009) 1.52
Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry (2002) 1.50
An association with great implications: vascular pathology and Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 1.50
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry (2005) 1.47
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank (2010) 1.46
Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol (2011) 1.45
Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord (2010) 1.42
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
Community Health Workers and Family Medicine Resident Education: Addressing the Social Determinants of Health. Fam Med (2016) 1.39
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis (2012) 1.39
RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med (2007) 1.38
Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett (2010) 1.35
Hippocampal sclerosis dementia with tauopathy. Brain Pathol (2003) 1.34
Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion (2006) 1.25
Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging (2005) 1.24
Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiol Aging (2008) 1.24
Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol (2006) 1.23
Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol Res (2005) 1.22
Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol (2010) 1.22
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J Neuroinflammation (2006) 1.20
Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis (2007) 1.20
Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology (2014) 1.19
Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol (2012) 1.18
APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry (2002) 1.18
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17